Clinical Trials Sponsored by Eisai Inc.

Total 35574 results

Eisai Limited

Completed

Extended Treatment in Metastatic Breast Cancer With Eribulin (EXTER)

Breast Cancer

Spain
Eisai GmbH

Completed

Incidence and Resolution of Eribulin-Induced Peripheral Neuropathy (IRENE)

Locally Advanced or Metastatic Breast Cancer

Germany
Eisai Inc.
Eisai Limited

Completed

Efficacy and Safety of Donepezil Hydrochloride in Preadolescent and Adolescent Children With Attention Impairment Following Cancer Treatment

Attention Impairment

United States, Netherlands, France, Spain, United Kingdom, Germany, Argentina, Canada, Australia, Chile
Eisai Inc.
Eisai Limited

Completed

Open-Label Extension Study of 23 mg Donepezil SR in Participants With Moderate to Severe Alzheimer's Disease

Alzheimer's Disease

United States
Eisai Limited

Completed

A Confirmation Study of Eribulin in Combination With Capecitabine

Metastatic Breast Cancer

United Kingdom, Bulgaria, Russian Federation
Eisai Limited

Completed

A Study of Perampanel as Add-on Therapy in Adult and Adolescent Participants With Focal Seizures

Partial Seizures
Eisai GmbH

Completed

ZEDEBAC: Zebinix Effects in Dependency of Baseline Conditions

Focal Epilepsy

Germany
Eisai Limited

Completed

The Effect of Vitamin K2 on Bone Turnover

Osteoporosis

Japan
Eisai Limited

Completed

A Placebo-Controlled, Double-Blind Comparative Study of E2080 in Lennox-Gastaut Syndrome Patients (Study E2080-J081-304)

Lennox-Gastaut Syndrome

Japan
Eisai Limited

Completed

To Assess the Effect of Rifampicin on the Pharmacokinetics of Eribulin Mesylate in Participants With Advanced Solid Tumors

Tumor

Netherlands
Eisai Limited

Terminated

Adjunctive Zonisamide in Primary Generalised Tonic Clonic Seizures

Epilepsy

Australia, Serbia, Germany, Czech Republic, Romania, Estonia, Lithuania, Croatia, Finland, Hungary, Poland, Russian Federation, Ukraine
Eisai Limited

Completed

European Registry of Anti-Epileptic Drug Use in Patients With Lennox-Gastaut Syndrome (LGS)

Lennox-Gastaut Syndrome

France, United Kingdom, Germany, Spain, Denmark, Austria, Italy, Sweden
Eisai Limited

Terminated

A Study to Evaluate the Safety and Tolerability and Explore the Efficacy of Zonisamide as add-on Therapy in Elderly Patients With Refractory Partial Seizures

Epilepsy

United Kingdom, Germany, Hungary, Switzerland, Italy, Netherlands, Poland
Eisai Limited

Completed

Pharmacokinetics and Food Effect of Single Oral Dose of E7050 in Healthy Volunteers

Healthy Subjects

Netherlands
Eisai Inc.
Eisai Limited

Completed

An Evaluation of the Efficacy and Safety of E2007 in Patients With Painful Diabetic Neuropathy

Diabetic Neuropathy

United States
Eisai Inc.
Eisai Limited

Completed

Comparison of 23 mg Donepezil Sustained Release (SR) to 10 mg Donepezil Immediate Release (IR) in Patients With Moderate to Severe Alzheimer's Disease

Alzheimer's Disease

United States
Eisai GmbH

Terminated

Efficacy and Safety of an add-on Treatment With Zonisamide in Adults With Focal Epileptic Seizures With or Without Secondary Generalization

Epilepsy

Germany
Eisai Limited

Completed

The Efficacy, Tolerability and Safety of Donepezil (Aricept) in Parkinson's Disease Patients With Dementia

Dementia With Parkinson's Disease

Germany, Ireland
Eisai Limited

Completed

A Study in Healthy Subjects to Determine the Effects When Alcohol is Administered With Perampanel

Central Nervous System

United Kingdom
Eisai Inc.
Eisai Limited

Completed

Study Investigating the Effect of E7337 on Tumor Like Lesions in Computed Tomography (CT) of the Liver

Lesions of the Liver

Japan
Eisai Limited

Completed

Randomized, Open, Parallel, Active Controlled Study on Fracture Prevention in Antiosteoporosis Treatment (OF Study)

Osteoporosis

Japan
Eisai Limited

Completed

An Open Label Phase II Study of Indisulam in Combination With Irinotecan in Patients With Metastatic Colorectal Cancer Who Have Been Previously Treated With 5-Fluorouracil/Leucovorin and Oxaliplatin

Colorectal Cancer

United Kingdom, France
Eisai Limited

Completed

A Study to Determine the Absolute Bioavailability and the Absorption, Metabolism, and Elimination Properties of Carbon-14 (14C)E7386 in Healthy Male Participants

Healthy Volunteers

United Kingdom
Eisai GmbH

Completed

A Study to Evaluate the Effectiveness of Perampanel as Only Add-on Treatment in Participants With Primary or Secondarily Generalized Tonic-clonic Seizures

Seizures

Germany
Eisai Limited

Completed

A Study to Determine the Metabolism and Elimination of [14C]E7090 in Healthy Male Participants

Healthy Volunteers

United Kingdom
Eisai Limited

Completed

A 24-weeks, Multi-center, Randomized, Double-blind, Placebo Controlled Study to Evaluate the Efficacy and Safety of Donepezil Hydrochloride in Chinese Subjects With Severe Alzheimer's Disease

Alzheimer's Type Dementia

China
Eisai Limited

Completed

Eribulin Use for the Treatment of Advanced Breast Cancer: A Prospective Observational Registry

Breast Cancer

United Kingdom, Denmark, Ireland
Eisai Limited

Terminated

Efficacy and Safety of Adjunctive Zonisamide in Myoclonic Seizures Associated With Idiopathic Generalised Epilepsy

Epilepsy

Australia, Serbia, Germany, Czech Republic, Romania, Estonia, Lithuania, Croatia, Finland, Hungary, Poland, Russian Federation, Ukraine
Eisai Limited

Completed

A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study of the Safety, Tolerability and Efficacy of E2007 in Parkinson's Disease Patients With "Wearing Off" Motor Fluctuations and "On" Period Dyskinesias

Parkinson's Disease

Czech Republic, France, Germany, Italy, Serbia, Spain
Eisai Limited

Terminated

Efficacy, Safety and Tolerability of E2007 in Levodopa Treated Parkinson's Disease Patients With Motor Fluctuations

Parkinson's Disease

France
Eisai Limited

Completed

Study of E7070 Combined With Capecitabine to Determine Efficacy and Recommended Dose of Combination in Patients With Metastatic Colorectal Cancer

Colorectal Cancer (CRC)

Netherlands, France, Germany
Eisai Limited

Completed

Evaluating the Pharmacokinetics and Tolerance of Co-administration of Oral Multiple Dose of Ketoconazole and an IV (Bolus) Infusion of Eribulin in Patients With Advanced Solid Tumors

Cancer

Netherlands
Eisai Limited

Completed

QT Interval Prolongation Study of Eribulin Mesylate (E7389) in Patients With Advanced Solid Tumors

Advanced Solid Tumor

France
Eisai Limited

Completed

A Randomized, Open, Parallel, Optimal Injection Rate-Finding Study for E7337 in Dynamic CT of the Liver in Patients With Liver Disease

Lesion

Japan
Eisai Limited

Completed

A Comparative Study of KES524 in Patients With Obesity Disease

Obesity

Japan
Eisai Limited

Terminated

A Phase II/III Clinical Study on Inhibitory Effects of E0167 on Recurrence of Hepatocellular Carcinoma

Hepatocellular Carcinoma

Japan
Eisai Inc.

Recruiting

A Study to Assess Safety and Target Engagement of E2814 in Participants With Mild to Moderate Cognitive Impairment Due to Dominantly Inherited Alzheimer's Disease

Alzheimer Disease

United States, United Kingdom
Eisai Inc.

Completed

A Study to Evaluate the Respiratory Safety of Lemborexant in Adult and Elderly Participants With Moderate to Severe Obstructive Sleep Apnea, and in Adult and Elderly Participants With Moderate to Severe Chronic Obstructive Pulmonary Disease

Sleep Apnea, Obstructive | Respiration Disorders | Pulmonary Disease, Chronic Obstructive

United States
Eisai Inc.

Completed

Study of Lenvatinib in Subjects With Advanced Endometrial Cancer and Disease Progression

Endometrial Cancer

United States, Poland, Ukraine, Bulgaria, Romania, Belgium, Russian Federation, Hungary
Eisai Inc.

Completed

A Study of Single-Agent Eribulin Mesylate as First-Line Therapy for Locally Recurrent or Metastatic Human Epidermal Growth Factor Receptor Two (HER2) Negative Breast Cancer

Locally Recurrent | Metastatic Breast Cancer ( HER2 Negative)

United States
Eisai Inc.

Completed

Phase 3 Study to Compare the Efficacy and Safety of Eribulin With Dacarbazine in Subjects With Soft Tissue Sarcoma

Soft Tissue Sarcoma

United States, France, United Kingdom, Germany, Spain, Belgium, Argentina, Israel, Poland, Romania, Korea, Republic of, Canada, Netherlands, Australia, New Zealand, Singapore, Brazil, Russian Federation, Austria, Thailand, Italy, ... and more
Eisai Inc.

Completed

A Randomized, Open-label, Multicenter, Phase 3 Study to Compare the Efficacy and Safety of Eribulin With Treatment of Physician's Choice in Subjects With Advanced Non-Small Cell Lung Cancer

Non-Small Cell Lung Cancer (NSCLC)

United States, Taiwan, Hong Kong, Spain, Poland, Singapore, Russian Federation, Italy, Australia, France, Germany, Japan, United Kingdom, Korea, Republic of
Eisai Inc.

Completed

Escalation Study to Determine Bioavailability of a Single Oral Dose of Decitabine in Patients With Myelodysplastic Syndrome (MDS)

Myelodysplastic Syndrome

United States
Eisai Inc.

Completed

A Post-marketing Observational Study Of The Use Of Zonisamide (ZNS) in the Adjunctive Treatment Of Adult Patients With Partial Onset Seizures (Study E2090-E044-410) (ZOOM)

Partial Onset Seizures

Germany, Sweden, Norway, Austria, Denmark
Eisai Inc.

Completed

Dose-Finding Study of E7070 in Combination With Irinotecan

Cancer

United States
Eisai Inc.

Available

An Extended Access Program (EAP) for Participants Who Have Completed Rufinamide Study E2080-G000-303

Lennox Gastaut Syndrome

Poland
Eisai Inc.

Completed

A Study to Assess the Safety and Tolerability of E2511 in Healthy Adult and Elderly Participants

Healthy Volunteers

United States
Eisai Inc.

Terminated

Efficacy and Safety of Decitabine as Epigenetic Priming With Induction Chemotherapy in Pediatric Acute Myelogenous Leukemia (AML) Subjects

Pediatric Acute Myelogenous Leukemia (AML)

United States, Canada, Australia
Eisai Inc.

Completed

Study to Evaluate the Efficacy and Safety of Perampanel as Monotherapy or First Adjunctive Therapy in Subjects With Partial Onset Seizures With or Without Secondarily Generalized Seizures or With Primary Generalized Tonic-Clonic Seizures

Partial Onset Seizures | Primary Generalized Tonic-Clonic Seizures | Secondarily Generalized Seizures

United States
Eisai Inc.

Terminated

Study to Evaluate the Efficacy and Safety of Belviq XR® in Conjunction With Lifestyle Modification for Weight Loss in Obese Adolescents, Age 12 to 17 Years

Obesity

United States

3

Subscribe